Incuron announces the receipt of a Notice of Allowance from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application (#124239) for CBL0137.


Incuron Announces Results in Study of Pediatric Neuroblastoma, that have been published in the journal Science Translational Medicine. The reported studies were led by scientists from the Children’s Cancer Institute–Australia (CCIA),Roswell Park Cancer Institute (RPCI) and Incuron.


Incuron, a joint subsidiary of the Bioprocess Capital Ventures closed-end investment fund and Cleveland BioLabs, Inc., announced updates on clinical progress with lead oncology program, CBL0137.

Page 1 of 3
You are here:   HomeNews